Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

March 21, 2019

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019

Read More

March 14, 2019

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA

Read More

March 6, 2019

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine  

Study Demonstrates that Clarified Testing Guidelines Can Identify More Couples at Risk of Passing on a Genetic Condition SALT LAKE CITY, March 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health

Read More

February 5, 2019

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Total Second-Quarter Revenues of $216.8 Million, Up 15 Percent Second-Quarter Diluted EPS of $0.03 and Adjusted EPS of $0.38, Up 6 Percent SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and

Read More

November 19, 2018

Myriad Announces $50 Million Accelerated Share Repurchase Program

SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A.

Read More

November 6, 2018

Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results

Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75 SALT

Read More

February 13, 2019

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at multiple upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer at Myriad Genetics will

Read More

January 28, 2019

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019

SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

December 31, 2018

Peter D. Meldrum (1947-2018)

Myriad Salutes the Life and Achievements of Its Co-Founder SALT LAKE CITY, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the company’s former CEO Peter Durkee Meldrum, age 71, passed away on Thursday, December 20, 2018.

Read More

March 21, 2019

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019

Read More

March 14, 2019

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA

Read More

March 6, 2019

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine  

Study Demonstrates that Clarified Testing Guidelines Can Identify More Couples at Risk of Passing on a Genetic Condition SALT LAKE CITY, March 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health

Read More

March 21, 2019

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019

Read More

March 14, 2019

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA

Read More

March 6, 2019

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine  

Study Demonstrates that Clarified Testing Guidelines Can Identify More Couples at Risk of Passing on a Genetic Condition SALT LAKE CITY, March 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health

Read More